Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
about
Proteomics and mass spectrometry for cancer biomarker discoveryProteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation.Differential protein expressions in breast cancer between drug sensitive tissues and drug resistant tissuesCytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes.Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer.Mechanistic Study of the Phytocompound, 2- β -D-Glucopyranosyloxy-1-hydroxytrideca-5,7,9,11-tetrayne in Human T-Cell Acute Lymphocytic Leukemia Cells by Using Combined Differential Proteomics and Bioinformatics Approaches.DAMTC regulates cytoskeletal reorganization and cell motility in human lung adenocarcinoma cell line: an integrated proteomics and transcriptomics approachBreast cancer proteomics: clinical perspectives.Assessment of Cytokeratin-19 Gene Expression in Peripheral Blood of Breast Cancer Patients and Breast Cancer Cell Lines.Clinical Significance of CK19 Negative Breast Cancer.Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry.Beyond laser microdissection technology: follow the yellow brick road for cancer research.Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.Proteomic analysis of tissue samples in translational breast cancer research.Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms.Differential Proteome Analysis of Extracellular Vesicles from Breast Cancer Cell Lines by Chaperone Affinity Enrichment.
P2860
Q28766969-2465F5F3-F271-4841-8D93-4E1E573B4631Q33236750-73C98075-C6A2-46A6-9D8A-FFF796CF5C74Q33667547-B1830C1B-6B3F-464C-B92C-BC39297E75BCQ33972987-EB3D4CD6-CEE5-41FC-B9A7-4C36E3A96E12Q35167598-517F9969-49A1-49A5-8099-67768EE6F6D0Q35991183-792E86ED-DF41-42FC-A7C0-86C444EE2470Q36236245-A2A3701B-248F-49F4-B238-E0F546AE54A3Q36347225-2BFA4FB1-49AB-44BA-8AE1-E2E30F4E52E1Q36717346-A220C550-0E75-47DE-A6A2-8263EF05FBC3Q36856910-C6D3E4DC-4F16-4BFA-952A-E44E3C21AD9BQ37061760-E01DA031-6F53-45E7-B7A5-D40A0B7FF314Q37212470-F689E019-071A-451A-8FA8-7A5E9DD262D0Q37516295-87D97436-0F58-4F58-813F-DCC6B7740163Q37529089-A78ED837-2316-409A-AF43-47126393BE1DQ38212502-A658BA21-F7E4-4274-9904-AEB2670DF9C1Q39258777-59BA9F36-6A61-4CE7-BA3B-6906206707A2Q47239080-9647E1A0-1369-4C9A-B4CC-92705F652390
P2860
Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Proteomics of breast cancer: e ...... type 2 positive breast tumors.
@ast
Proteomics of breast cancer: e ...... type 2 positive breast tumors.
@en
type
label
Proteomics of breast cancer: e ...... type 2 positive breast tumors.
@ast
Proteomics of breast cancer: e ...... type 2 positive breast tumors.
@en
prefLabel
Proteomics of breast cancer: e ...... type 2 positive breast tumors.
@ast
Proteomics of breast cancer: e ...... type 2 positive breast tumors.
@en
P2093
P2860
P356
P1433
P1476
Proteomics of breast cancer: e ...... type 2 positive breast tumors.
@en
P2093
Dao-Hai Zhang
Evelyn S C Koay
Lee Kian Tai
Lee Lee Wong
Sunil K Sethi
P2860
P304
P356
10.1002/PMIC.200401069
P577
2005-05-01T00:00:00Z